Bio‑Rad EVP Courtney Enloe Receives RSUs, Exercises Derivatives

What Happened Courtney C. Enloe, EVP, General Counsel & Secretary of Bio‑Rad Laboratories (BIO), received a grant of 2,876 restricted stock units (RSUs) and had derivative shares convert/vest. On Sept 5–6, 2026 a total of 1,453 derivative shares were converted (685 + 768) at $0.00 per share (reflecting vested RSUs/derivative conversions). To satisfy tax withholding, 551 shares were surrendered/withheld (246 on Sept 5 and 305 on Sept 6) at $386.11 per share, generating proceeds of $94,983 and $117,764 respectively (total tax withholding value = $212,747).

These transactions are primarily acquisitions/vests (awarded/converted shares); the only disposals were routine tax-withholding withholding of shares (not open-market sales).

Key Details

• Transaction dates: Grant reported 2026-09-04; conversions/exercises on 2026-09-05 and 2026-09-06; Form filed 2026-09-09.
• Specifics:
  • 2,876 RSUs granted (2026-09-04) — acquired, $0.00 per share (derivative award).
  • 685 derivative shares converted (2026-09-05) — acquired at $0.00; 246 shares withheld for taxes at $386.11 ($94,983).
  • 768 derivative shares converted (2026-09-06) — acquired at $0.00; 305 shares withheld for taxes at $386.11 ($117,764).
• Total derivative shares converted: 1,453. Total shares withheld for taxes: 551 for ~$212,747.
• Shares owned after the transaction: Not disclosed in the provided filing excerpts.
• Footnotes: RSUs are a contingent right to one share each (F1–F2). The RSUs vest over four years (25% on first anniversary, then equal quarterly installments or 25% per year as described) (F3–F4).
• Filing timeliness: Form filed 2026-09-09 covering transactions in early Sept; the filing itself does not include a late-filing notation in the provided data.

Context

• The $0.00 per-share conversions indicate vesting/conversion of RSUs or similar derivative awards rather than a cash purchase. Some shares were surrendered/withheld to cover tax withholding obligations (transaction code F), which is routine and not the same as an open-market sale.
• These entries reflect compensation/vesting activity by an executive, which is informative about compensation realization but not necessarily a signal of a change in insider sentiment.